===Esperion Therapeutics (ESPR) : new drug submissions in Canada for NEXLETOL treatments

Co announced that it has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.